MENU
+Compare
VRDN
Stock ticker: NASDAQ
AS OF
Aug 21 closing price
Price
$18.02
Change
-$0.12 (-0.66%)
Capitalization
1.47B

VRDN Viridian Therapeutics Forecast, Technical & Fundamental Analysis

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease... Show more

Industry: #Biotechnology
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for VRDN with price predictions
Aug 21, 2025

VRDN's RSI Indicator leaves overbought zone

The 10-day RSI Oscillator for VRDN moved out of overbought territory on July 24, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 instances where the indicator moved out of the overbought zone. In of the 34 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 57 cases where VRDN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for VRDN turned negative on August 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRDN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VRDN broke above its upper Bollinger Band on August 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 12, 2025. You may want to consider a long position or call options on VRDN as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where VRDN advanced for three days, in of 255 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 150 cases where VRDN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRDN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.511) is normal, around the industry mean (19.773). P/E Ratio (0.000) is within average values for comparable stocks, (54.197). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.633). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. VRDN's P/S Ratio (5000.000) is very high in comparison to the industry average of (300.579).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRDN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

VRDN is expected to report earnings to -100 cents per share on November 18

Viridian Therapeutics VRDN Stock Earnings Reports
Q3'25
Est.
$-1.01
Q2'25
Est.
$-1.00
Q1'25
Beat
by $0.11
Q4'24
Beat
by $0.22
Q3'24
Missed
by $0.09
The last earnings report on August 06 showed earnings per share of -100 cents, meeting the estimate of -100 cents. With 668.82K shares outstanding, the current market capitalization sits at 1.47B.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
221 Crescent Street
Phone
+1 617 272-4600
Employees
94
Web
https://www.viridiantherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PLSAX30.98N/A
N/A
Principal Large Cap S&P 500 Index A
FICEX16.97N/A
N/A
Frost Growth Equity Inst
MLPTX9.66N/A
N/A
Invesco SteelPath MLP Select 40 Y
THMEX15.84N/A
N/A
CCT Thematic Equity Institutional
TIGCX21.88-0.09
-0.41%
Thornburg International Growth C

VRDN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with AURA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-0.66%
AURA - VRDN
51%
Loosely correlated
+1.57%
DSGN - VRDN
50%
Loosely correlated
+7.52%
DNLI - VRDN
50%
Loosely correlated
+4.96%
SYRE - VRDN
49%
Loosely correlated
+2.63%
NRIX - VRDN
47%
Loosely correlated
+1.26%
More